DANIEL J BOOSER to Humans
This is a "connection" page, showing publications DANIEL J BOOSER has written about Humans.
Connection Strength
0.133
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
Score: 0.005
-
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
Score: 0.004
-
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):6-8.
Score: 0.004
-
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001 May; 108(5):994-5.
Score: 0.004
-
Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol. 2000 Feb; 23(1):40-1.
Score: 0.003
-
Phase I study of liposomal annamycin. Cancer Chemother Pharmacol. 2000; 46(5):427-32.
Score: 0.003
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
Score: 0.003
-
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
Score: 0.003
-
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52.
Score: 0.002
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.002
-
Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs. 1994 Feb; 47(2):223-58.
Score: 0.002
-
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract. 2014 Apr; 20(2):120-9.
Score: 0.002
-
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. 2013 Jun; 30(5):631-42.
Score: 0.002
-
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol. 2013 Jan 11; 8:13.
Score: 0.002
-
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
Score: 0.002
-
Treatment of locally advanced breast cancer. Semin Oncol. 1992 Jun; 19(3):278-85.
Score: 0.002
-
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012 Jul; 134(1):333-43.
Score: 0.002
-
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
Score: 0.002
-
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34.
Score: 0.002
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.002
-
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2012 May 01; 118(9):2378-84.
Score: 0.002
-
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
Score: 0.002
-
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
Score: 0.002
-
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5.
Score: 0.002
-
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011 Feb 02; 103(3):264-72.
Score: 0.002
-
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010 Sep 20; 28(27):4111-9.
Score: 0.002
-
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 Mar 15; 116(6):1440-5.
Score: 0.002
-
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer. 2010 Mar 01; 116(5):1210-7.
Score: 0.002
-
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5.
Score: 0.002
-
Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer. 2009 Aug; 9(3):173-7.
Score: 0.002
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
Score: 0.002
-
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21.
Score: 0.002
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
Score: 0.002
-
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008 Oct; 19(10):1713-9.
Score: 0.002
-
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11.
Score: 0.001
-
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2007 Jun; 60(1):61-7.
Score: 0.001
-
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Sep 01; 107(5):935-44.
Score: 0.001
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
Score: 0.001
-
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006 Jun 01; 106(11):2327-36.
Score: 0.001
-
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006 May; 17(5):813-7.
Score: 0.001
-
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91.
Score: 0.001
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92.
Score: 0.001
-
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72.
Score: 0.001
-
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005 May 01; 103(9):1763-9.
Score: 0.001
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.001
-
Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D. 2005; 6(5):299-305.
Score: 0.001
-
A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5425-31.
Score: 0.001
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
Score: 0.001
-
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102.
Score: 0.001
-
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61.
Score: 0.001
-
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36.
Score: 0.001
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.001
-
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34.
Score: 0.001
-
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23.
Score: 0.001
-
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14.
Score: 0.001
-
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
Score: 0.001
-
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002 Nov; 8(11):3407-18.
Score: 0.001
-
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002 Jun; 109(6):1188-91.
Score: 0.001
-
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
Score: 0.001
-
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer. 2002 May 01; 94(9):2321-6.
Score: 0.001
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01; 20(7):1800-8.
Score: 0.001
-
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21.
Score: 0.001
-
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol. 2002 Apr; 49(4):299-302.
Score: 0.001
-
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
Score: 0.001
-
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol. 2001 Apr 01; 19(7):2002-9.
Score: 0.001
-
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1716-22.
Score: 0.001
-
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33.
Score: 0.001
-
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
Score: 0.001
-
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
Score: 0.001
-
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000 May 01; 88(9):2054-60.
Score: 0.001
-
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
Score: 0.001
-
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.
Score: 0.001
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
Score: 0.001
-
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
Score: 0.001
-
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
Score: 0.001
-
Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar; 17(3):855-61.
Score: 0.001
-
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct; 16(10):3362-8.
Score: 0.001
-
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21.
Score: 0.001
-
Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995 Oct; 4(4):715-34.
Score: 0.001
-
Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):185-7.
Score: 0.001
-
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 1995 Jul 15; 55(14):3060-7.
Score: 0.001
-
Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41.
Score: 0.001
-
Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol. 1994; 353:193-202.
Score: 0.001
-
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan; 12(1):50-4.
Score: 0.001
-
Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6.
Score: 0.001
-
G6PD Toronto. Biochem Genet. 1973 Mar; 8(3):259-65.
Score: 0.001
-
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
Score: 0.001
-
Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer. 1989 Nov 15; 64(10):1995-2000.
Score: 0.000
-
Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988 Jan; 14(1):43-8.
Score: 0.000
-
Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1985 Mar; 11(3):511-9.
Score: 0.000
-
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer. Am J Clin Oncol. 1984 Jun; 7(3):241-4.
Score: 0.000
-
Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin. Cancer Treat Rep. 1984 Apr; 68(4):671-3.
Score: 0.000
-
Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol. 1984; 2(3):253-9.
Score: 0.000